Article Data

  • Views 1622
  • Dowloads 112

Original Research

Open Access

ngenol derivatives inhibit proliferation and induce apoptosis in breast cancer cell lines

  • A. Vigone1,*,
  • G.C. Tron1
  • D. Surico1
  • G. Baj1
  • G. Appendino2
  • N. Surico1

1Department of Obstetrics and Gynaecology, Italy

2Department of Pharmaceutical Technologies and Sciences, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy

DOI: 10.12892/ejgo200505526 Vol.26,Issue 5,September 2005 pp.526-530

Published: 10 September 2005

*Corresponding Author(s): A. Vigone E-mail:

PDF (562.65 kB) View Full-text

Abstract

We present an analysis of the antitumour effects of a library of ingenol derivatives synthesized in our laboratory and published elsewhere. Fluoro-ingenol (1), ingenol-20-deoxy-20-phtalimido (2), ingenol-3-benzoate-20-deoxy-20-benzamide (3), ingenol-3-benzoate (4), ingenol-3,5-dibenzoate (5), ingenol-3,20-dibenzoate (6), 20-deoxy-20-benylureidoingenol-3-benzoate (7), ingenol-20-deoxy-20-fluoro-3-benzoate (8), ingenol-20-deoxy-20-fluoro-3,5-dibenzoate (9), ingenol-20-phenylcarbamate (10), ingenol-20-benzoate (11), ingenol-3-benzoate-20-phenylcarbamate (12) were tested in vitro on two well characterized breast cancer cell (BCC) lines, namely T47D and MDA-MB-231, as representative of two opposite types of hormone-sensitiveness and differentiation stage. These experiments led us to identify ingenol-20-benzoate (11) as a promising antitumour compound characterized by a relevant inhibition of cell growth and apoptotic cell death involving a p53-mediated pathway.

Keywords

Apoptosis; Breast cancer; Chemotherapy; Ingenol; PKC

Cite and Share

A. Vigone, G.c. Tron, D. Surico, G. Baj, G. Appendino, N. Surico. ngenol derivatives inhibit proliferation and induce apoptosis in breast cancer cell lines. European Journal of Gynaecological Oncology. 2005; 26(5): 526-530. doi: 10.12892/ejgo200505526

References

[1] Zechmeister K., Brandl F., Hoppe W., Hecker E., Opferkuch H.J., Adolf W.: "Structure determination of new tetraacyclic diterpene ingenol triacetate with triple product methods". Tetrahedron Letters, 1970, 47, 4075.

[2] Nishizuka Y.: "Studies and perspectives of protein kinase C" Science, 1986, 233, 305.

[3] Mbwambo Z.H., Lee S.K., Mshiu E.N., Pezzuto J.M., Kinghorn A.O.: "Constituents from the stem wood of Euphorbia quinquecostata with phorbol dibutyrate receptor-binding inhibitory activity". J. Nat. Prod., 1996, 59, 1051.

[4] Kupchan S.M., Uchida I., Branfman A.R., Dailey R.G. Jr., Fei B.Y.: "Antileukemic principles isolated from euphorbiaceae plants". Science, 1976, 191, 571.

[5] ltokawa H., Ichihara Y., Watanabe K., Takeya K.: "An antitumour principle from Euphorbia lathyris". Planta Med., 1989, 55, 271.

[6] Fujiwara M., Ijichi K., Katsuura K., Wang G.Y.S., Uemura D. et al.: "Ingenol derivatives are highly potent and selective inhibitors of HIV replication in vitro". Antiviral Chem. Chemother., 1996, 7, 230.

[7] Nakamura H., Kishi Y., Pa」ares M.A., Rando R.R.: "Structural basis of protein kinase C activation by tumour promoters". Proc Natl. Acad. Sci USA, 1989, 86, 9672.

[8] Appendino G., Tron G.C., Cravotto G., Palmisano G., Annunziata R., Baj G. et al.: "Synthesis of modified ingenol esters". Eur. J. Organic Chem., 1999, 12, 3413.

[9] Kelsey J.L., Bernstein L.: "Epidemiology and prevention of breast cancer". Ann. Rev. Public Health., 1996, 17, 47.

[10] Gibbs J.B.: "Mechanism-based target identification and drug discovery in cancer research". Science, 2000, 287, 1969.

[11] Baj G., Arnulfo A., Deaglio S., Mallone R., Vigone A., Rosa M. et al.: "Retinoids in breast cancer prevention and treatment. A review of the literature". Eur. J. Gynaecol. Oncol., 2000, 21, 411.

[12] Darzynkiewicz Z., Bruno S., Del Bino G., Gorczyca W., Hotz M.A., Lassota P. et al.: "Features of apoptotic cells measured by flow cytometry". Cytometry, 1992, 13, 795.

[13] Ahmed S.A., Gogal R.M. Jr., Walsh J.E.: "A new rapid and simple non-radioactive assay to monitor and determine the proliferation of lymphocytes: an alternative to[3H]thymidine incorporation assay". J. lmmunol. Methods, 1994, 170, 211.

[14] Nociari M.M., Shalev A., Benias P., Russo C.: "A novel one-step, highly sensitive fluorometric assay to evaluate cell-mediated cytotoxicity". J. lmmunol. Methods, 1998, 213, 157.

[15] Deaglio S., Mallone R., Baj G., Donati D., Giraudo G., Como F. et al.: "Human CD38 and its ligand CD31 define a unique lamina propria T lymphocyte signaling pathway". FASEB J., 2001, 15, 580.

[16] Baj G., Arnulfo A., Deaglio S., Mallone R., Vigone A., De Cesaries M.G. et al.: "Arsenic trioxide and breast cancer. Analysis of the apoptotic differentiative and irnrnunornodulatory effects". Breast Cancer Res. Treat., 2002, 73, 61.

[17] Zhang G.C., Kazanietz M.G., Blumberg P.M., Hurley J.H.: "Crystal structure of the cys2 activator-binding domain of protein kinase C delta in complex with phorbol ester". Cell, 1995, 81, 917.

Submission Turnaround Time

Top